Research Article
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort
Table 2
Patient demographics at the diagnosis of LN.
| Demographics | |
| Female | 87 (86.1%) | Ethnicity | | Caucasian | 63 (62.4%) | Black | 18 (17.8%) | Asian | 12 (11.9%) | Others | 8 (7.9%) | Age at SLE diagnosis (years) | 28.64 ± 10.89 | Age at LN (years) | 32.99 ± 10.66 | Disease duration at LN (years) | 4.36 ± 4.60 | Disease scores | | SLEDAI-2K at LN diagnosis | 13.29 ± 7.14 | SDI at LN diagnosis | 0.44 ± 0.95 | Treatment | | Treated with glucocorticoids at LN | 93 (92.1%) | Treated with antimalarials at LN | 52 (51.5%) | Treated with immunosuppressives at LN | 60 (59.4%) | Treated with ACE inhibitor/ARB | 40 (39.6%) | Laboratory tests at LN diagnosis | | 24H-P (g/d) median (interquartile range) | 1.5 (0.9–2.9) | 24H-P (g/d) mean at baseline | 2.36 ± 2.31 | 24H-P (g/d) mean at year 1 | 1.17 ± 1.59 | uRBCs (hpf) median (interquartile range) | 5.0 (0.0–10.0) | Cr (mmol/L) median (interquartile range) | 72.0 (64.0–89.0) |
|
|